Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID B KUDROW

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1952407488
CMS profile
179641
Location
SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$134,982.28

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $36,005.10 28
AbbVie Inc. $35,749.15 42
Biohaven Pharmaceuticals, Inc. $28,066.59 31
Lilly USA, LLC $16,734.32 18
BioDelivery Sciences International, Inc. $9,995.04 10
Teva Pharmaceuticals USA, Inc. $3,460.00 2
Eli Lilly and Company $2,025.00 1
Allergan, Inc. $1,750.00 1
Lundbeck LLC $1,197.08 1

Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID B KUDROW

NPI 1952407488 · CMS profile ID 179641

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952407488?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID B KUDROW, NPI 1952407488, CMS profile ID 179641. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952407488?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID B KUDROW, NPI 1952407488, CMS profile ID 179641. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952407488?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID B KUDROW, NPI 1952407488, CMS profile ID 179641, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 134 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1952407488?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $134,982.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $1,800.0010/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250785 CMS
Amgen Inc. $2,700.0010/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250809 CMS
Amgen Inc. $2,700.0010/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250813 CMS
Amgen Inc. $2,700.0010/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250817 CMS
AbbVie Inc. $1,750.0010/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172293 CMS
Lilly USA, LLC $28.1410/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819053471 CMS
AbbVie Inc. $1,800.0010/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172289 CMS
Amgen Inc. $264.5409/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250797 CMS
Amgen Inc. $518.1509/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250769 CMS
Amgen Inc. $106.5709/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250821 CMS
Amgen Inc. $18.7609/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250825 CMS
Amgen Inc. $121.8309/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250789 CMS
Amgen Inc. $79.4709/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250793 CMS
AbbVie Inc. $11.0709/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172285 CMS
Lilly USA, LLC $900.0009/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818904937 CMS
Lilly USA, LLC $900.0009/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819053477 CMS
Lilly USA, LLC $40.3208/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819060353 CMS
Lilly USA, LLC $1,800.0008/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819048365 CMS
Lilly USA, LLC $1,125.0008/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819053467 CMS
AbbVie Inc. $18.6608/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172281 CMS
Lilly USA, LLC $900.0008/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819048361 CMS
Amgen Inc. $360.2708/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825250765 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0008/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542623 CMS
Biohaven Pharmaceuticals, Inc. $28.0908/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542625 CMS
Lilly USA, LLC $450.0007/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819060349 CMS
AbbVie Inc. $2,400.0007/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172273 CMS
AbbVie Inc. $124.9907/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172277 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0007/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542599 CMS
Biohaven Pharmaceuticals, Inc. $193.4807/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542601 CMS
Biohaven Pharmaceuticals, Inc. $292.3307/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542603 CMS
Biohaven Pharmaceuticals, Inc. $30.1407/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542605 CMS
Biohaven Pharmaceuticals, Inc. $4,000.0007/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542607 CMS
Biohaven Pharmaceuticals, Inc. $193.4807/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542609 CMS
Biohaven Pharmaceuticals, Inc. $292.3307/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542611 CMS
Biohaven Pharmaceuticals, Inc. $176.2107/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542613 CMS
Biohaven Pharmaceuticals, Inc. $84.1207/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542615 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0007/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542617 CMS
Biohaven Pharmaceuticals, Inc. $65.9507/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542619 CMS
Biohaven Pharmaceuticals, Inc. $21.0607/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542621 CMS
AbbVie Inc. $27.6607/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172269 CMS
AbbVie Inc. $18.1207/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172265 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0007/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542595 CMS
Biohaven Pharmaceuticals, Inc. $27.1107/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542597 CMS
AbbVie Inc. $16.7207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172257 CMS
AbbVie Inc. $7.5007/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795172261 CMS
Eli Lilly and Company $2,025.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819048137 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0006/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542591 CMS
Biohaven Pharmaceuticals, Inc. $34.6006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542593 CMS
Lilly USA, LLC $900.0006/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819049359 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0006/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852542587 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $167,805.48 237
PY2020 $91,281.14 129
PY2021 $134,982.28 134
PY2022 $64,190.78 140
PY2023 $22,679.34 121
PY2024 $14,092.36 44
PY2025 $36,590.01 77

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,373.55 6
PY2025 Principal investigator $2,145,953.46 1,037
PY2024 Recipient $11,292.16 7
PY2024 Principal investigator $5,568,873.86 1,481
PY2023 Recipient $9,318.00 4
PY2023 Principal investigator $2,474,512.32 276
PY2022 Recipient $548.00 1
PY2022 Principal investigator $92,177.65 13
PY2021 Recipient $49.88 1
PY2021 Principal investigator $620,867.12 23
PY2020 Recipient $40,740.80 14
PY2020 Principal investigator $1,164,736.70 28
PY2019 Recipient $222,496.51 37
PY2019 Principal investigator $174,340.10 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

1,043 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,545.00 12/31/2025 Non-covered Recipient Entity
LISA G COOK MD INC
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202532961
Principal investigator 1 Travere Therapeutics, Inc. $5,921.16 12/17/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184239
Principal investigator 1 Travere Therapeutics, Inc. $78,187.84 12/17/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184244
Principal investigator 1 Travere Therapeutics, Inc. $876.72 12/11/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184232
Principal investigator 1 Travere Therapeutics, Inc. $104,316.74 12/11/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184235
Principal investigator 1 Merz Pharmaceuticals, LLC $2,525.98 12/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647239
Principal investigator 1 Eli Lilly and Company $100,282.90 12/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) No dispute reported 06/30/2026 1187883690
Principal investigator 1 PFIZER INC. $184.30 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703164
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703166
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703168
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703170
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703172
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703174
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703176
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703262
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703264
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703266
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703268
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703270
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703272
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703276
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703340
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703342
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703344
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703346
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703348
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703350
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703352
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703354
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703392
Principal investigator 1 PFIZER INC. $180.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703394
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703396
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703398
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703400
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703402
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703404
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703406
Principal investigator 1 PFIZER INC. $184.30 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703408
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703450
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703452
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703454
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703456
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703458
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703460
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703462
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703464
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703466
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703506
Principal investigator 1 PFIZER INC. $196.45 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703508
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703510
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703512
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703514
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703516
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703518
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703520
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703522
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703584
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703586
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703588
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703590
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703592
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703594
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703596
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703598
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703600
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703634
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703636
Principal investigator 1 PFIZER INC. $180.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703638
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703640
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703642
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703644
Principal investigator 1 PFIZER INC. $196.45 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703648
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703682
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703684
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703686
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703688
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703690
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703692
Principal investigator 1 PFIZER INC. $227.50 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703726
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703728
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703730
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703756
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703758
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703794
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703796
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703798
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703800
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703802
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703804
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703806
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703808
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703810
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703812
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703842
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703844
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703846
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703850
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703852
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703884
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703886
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703888
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703892
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703924
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703926
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703928
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703930
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703956
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703958
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703960
Principal investigator 1 PFIZER INC. $318.36 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703962
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703964
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703966
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703968
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703970
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703972
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703974
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703976
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703978
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704010
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704050
Principal investigator 1 PFIZER INC. $150.55 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704052
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704054
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704056
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704058
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704060
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704092
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704094
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704096
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704132
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704134
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704136
Principal investigator 1 PFIZER INC. $150.55 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704138
Principal investigator 1 PFIZER INC. $97.90 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704164
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704166
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704218
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704220
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704224
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704226
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704228
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704256
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704258
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704260
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704298
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704300
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704302
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704304
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704306
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704384
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704386
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704388
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704390
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704392
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704394
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704466
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704470
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704472
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704474
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704476
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704480
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704482
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705548
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705550
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705680
Principal investigator 1 PFIZER INC. $227.50 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705684
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705686
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705688
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705690
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705744
Principal investigator 1 PFIZER INC. $201.18 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705746
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705748
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705750
Principal investigator 1 PFIZER INC. $97.90 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705804
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705806
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705864
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705866
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705868
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705870
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705872
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705874
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705876
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705878
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705882
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706085
Principal investigator 1 PFIZER INC. $201.18 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706089
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706094
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706098
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706102
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706106
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706223
Principal investigator 1 PFIZER INC. $124.90 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706227
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706231
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706324
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706328
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706333
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706337
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706341
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706345
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706347
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706351
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706458
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706461
Principal investigator 1 PFIZER INC. $16.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706465
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706469
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706473
Principal investigator 1 PFIZER INC. $171.60 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706477
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706518
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706522
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706526
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706529
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706607
Principal investigator 1 PFIZER INC. $193.05 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706611
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706615
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706622
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706625
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706683
Principal investigator 1 PFIZER INC. $135.85 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706685
Principal investigator 1 PFIZER INC. $124.90 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706687
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706689
Principal investigator 1 PFIZER INC. $144.95 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706691
Principal investigator 1 PFIZER INC. $72.80 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706693
Principal investigator 1 PFIZER INC. $28.00 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706695
Principal investigator 1 PFIZER INC. $120.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706697
Principal investigator 1 PFIZER INC. $159.25 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706699
Principal investigator 1 PFIZER INC. $140.92 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706805
Principal investigator 1 PFIZER INC. $318.36 12/06/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706807
Principal investigator 1 Travere Therapeutics, Inc. $6,232.65 12/03/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184228
Principal investigator 1 Travere Therapeutics, Inc. $3,375.07 11/19/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244187358
Principal investigator 1 Travere Therapeutics, Inc. $90,794.21 11/19/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244187362
Principal investigator 1 Travere Therapeutics, Inc. $16,866.42 11/19/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244187367
Principal investigator 1 Merz Pharmaceuticals, LLC $24,629.25 11/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647241
Principal investigator 1 Merz Pharmaceuticals, LLC $19,969.14 11/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647243
Principal investigator 1 PFIZER INC. $450.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703178
Principal investigator 1 PFIZER INC. $450.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703274
Principal investigator 1 PFIZER INC. $1,200.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703646
Principal investigator 1 PFIZER INC. $1,500.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703848
Principal investigator 1 PFIZER INC. $2,275.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703890
Principal investigator 1 PFIZER INC. $1,000.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703894
Principal investigator 1 PFIZER INC. $5,000.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704222
Principal investigator 1 PFIZER INC. $450.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704308
Principal investigator 1 PFIZER INC. $450.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704468
Principal investigator 1 PFIZER INC. $1,000.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704478
Principal investigator 1 PFIZER INC. $4,000.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705682
Principal investigator 1 PFIZER INC. $450.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706235
Principal investigator 1 PFIZER INC. $450.00 10/23/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706619
Principal investigator 1 Travere Therapeutics, Inc. $44,445.03 10/22/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244187344
Principal investigator 1 Travere Therapeutics, Inc. $5,086.16 10/22/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244187348
Principal investigator 1 Travere Therapeutics, Inc. $6,631.20 10/22/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244187353
Recipient PFIZER INC. $330.00 10/14/2025 Covered Recipient Physician ZAVEGEPANT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228723140
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 10/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647245
Principal investigator 1 Merz Pharmaceuticals, LLC $7,000.00 10/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647247
Principal investigator 1 ABBVIE INC. $1,884.60 10/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LLC
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202513491
Principal investigator 1 ABBVIE INC. $3,475.00 09/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LLC
The purpose of this study is to evaluate mass balance pharmacokinetics and safety of [14C] ABBV-552 in healthy male volunteers following administration of a single oral dose No dispute reported 06/30/2026 1202512544
Principal investigator 1 Travere Therapeutics, Inc. $8,336.04 09/24/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244187335
Principal investigator 1 Travere Therapeutics, Inc. $82,148.09 09/24/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244187339
Principal investigator 1 Merz Pharmaceuticals, LLC $7,000.00 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647235
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647237
Principal investigator 1 ABBVIE INC. $1,350.00 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LLC
The purpose of this study is to evaluate mass balance pharmacokinetics and safety of [14C] ABBV-552 in healthy male volunteers following administration of a single oral dose No dispute reported 06/30/2026 1202506241
Principal investigator 1 ABBVIE INC. $450.00 08/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LLC
The purpose of this study is to evaluate mass balance pharmacokinetics and safety of [14C] ABBV-552 in healthy male volunteers following administration of a single oral dose No dispute reported 06/30/2026 1202505649
Principal investigator 1 Travere Therapeutics, Inc. $10,908.95 08/21/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244187324
Principal investigator 1 Travere Therapeutics, Inc. $79,979.10 08/21/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244187328
Principal investigator 1 Travere Therapeutics, Inc. $8,902.54 08/21/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244187332
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 07/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743727
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 07/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743729
Principal investigator 1 Travere Therapeutics, Inc. $100,625.41 07/23/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244187311
Principal investigator 1 Travere Therapeutics, Inc. $8,902.54 07/23/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244187316
Principal investigator 1 Travere Therapeutics, Inc. $7,085.58 07/23/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244187319
Recipient UCB Biosciences Inc. $7,108.00 07/23/2025 Covered Recipient Physician AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY PHASE 3 No dispute reported 06/30/2026 1246451689
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703144
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703190
Principal investigator 1 PFIZER INC. $881.10 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703740
Principal investigator 1 PFIZER INC. $881.10 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703764
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703826
Principal investigator 1 PFIZER INC. $1,768.05 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703834
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704086
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704296
Principal investigator 1 PFIZER INC. $1,768.05 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704310
Principal investigator 1 PFIZER INC. $25.00 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704318
Principal investigator 1 PFIZER INC. $25.00 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704488
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705754
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705890
Principal investigator 1 PFIZER INC. $300.00 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706354
Principal investigator 1 PFIZER INC. $25.00 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706484
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706597
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706701
Principal investigator 1 PFIZER INC. $193.70 07/22/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706797
Principal investigator 1 PFIZER INC. $1,980.00 07/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703156
Principal investigator 1 PFIZER INC. $375.00 07/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703214
Principal investigator 1 PFIZER INC. $218.00 07/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703656
Principal investigator 1 PFIZER INC. $1,500.00 07/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705470
Principal investigator 1 PFIZER INC. $390.50 07/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705656
Principal investigator 1 Travere Therapeutics, Inc. $8,902.54 06/16/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184296
Principal investigator 1 Travere Therapeutics, Inc. $125,359.83 06/13/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184288
Principal investigator 1 Travere Therapeutics, Inc. $9,667.52 06/13/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184292
Principal investigator 1 ABBVIE INC. $105.00 06/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LLC
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202490983
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,020.00 06/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LOS ANGELES
a phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult participants with episodic migraine No dispute reported 06/30/2026 1185540597
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16.80 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743642
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7.20 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743644
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743661
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.21 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743663
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $131.50 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743667
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743669
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743671
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $26.75 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743675
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16.80 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743677
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743683
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743687
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16.80 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743689
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8.40 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743691
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743697
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743701
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743703
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743705
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16.80 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743713
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12.00 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743717
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743721
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $131.50 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743723
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743725
Principal investigator 1 Travere Therapeutics, Inc. $8,902.54 05/30/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184283
Principal investigator 1 PFIZER INC. $100.00 05/17/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703356
Principal investigator 1 Travere Therapeutics, Inc. $88,029.58 05/15/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184273
Principal investigator 1 Travere Therapeutics, Inc. $9,491.51 05/15/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184277
Principal investigator 1 ABBVIE INC. $4,843.80 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LLC
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202484159
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743638
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743640
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743646
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743648
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743650
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743652
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743655
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743657
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743659
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743665
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743673
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743679
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743681
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743685
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743693
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743695
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743699
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743707
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743709
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743711
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743715
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 04/30/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743719
Recipient Ipsen Innovation $1,121.85 04/28/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291852
Recipient Ipsen Innovation $1,121.85 04/28/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291854
Recipient Ipsen Innovation $1,121.85 04/28/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291856
Principal investigator 1 Ipsen Innovation $481.40 04/25/2025 Non-covered Recipient Entity
Bnl Health, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289324
Principal investigator 1 Ipsen Innovation $180.00 04/24/2025 Non-covered Recipient Entity
Bnl Health, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289320
Principal investigator 1 Ipsen Innovation $300.00 04/24/2025 Non-covered Recipient Entity
Bnl Health, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289322
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703140
Principal investigator 1 PFIZER INC. $210.40 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703142
Principal investigator 1 PFIZER INC. $96.48 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703146
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703150
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703152
Principal investigator 1 PFIZER INC. $96.48 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703158
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703160
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703180
Principal investigator 1 PFIZER INC. $200.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703182
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703184
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703186
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703188
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703192
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703216
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703218
Principal investigator 1 PFIZER INC. $300.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703220
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703224
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703226
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703228
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703232
Principal investigator 1 PFIZER INC. $103.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703234
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703236
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703238
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703244
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703248
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703250
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703252
Principal investigator 1 PFIZER INC. $100.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703254
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703256
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703278
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703280
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703282
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703314
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703316
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703318
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703322
Principal investigator 1 PFIZER INC. $300.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703324
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703328
Principal investigator 1 PFIZER INC. $120.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703330
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703334
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703336
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703358
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703360
Principal investigator 1 PFIZER INC. $120.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703362
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703364
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703372
Principal investigator 1 PFIZER INC. $103.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703374
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703376
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703378
Principal investigator 1 PFIZER INC. $120.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703382
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703384
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703386
Principal investigator 1 PFIZER INC. $207.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703388
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703390
Principal investigator 1 PFIZER INC. $103.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703426
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703428
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703430
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703432
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703436
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703440
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703442
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703444
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703446
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703448
Principal investigator 1 PFIZER INC. $207.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703496
Principal investigator 1 PFIZER INC. $207.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703498
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703500
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703504
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703556
Principal investigator 1 PFIZER INC. $120.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703558
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703560
Principal investigator 1 PFIZER INC. $1,658.70 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703562
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703564
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703566
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703568
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703570
Principal investigator 1 PFIZER INC. $172.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703572
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703574
Principal investigator 1 PFIZER INC. $103.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703582
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703624
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703626
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703650
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703652
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703654
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703658
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703660
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703662
Principal investigator 1 PFIZER INC. $96.48 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703664
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703666
Principal investigator 1 PFIZER INC. $96.48 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703668
Principal investigator 1 PFIZER INC. $96.48 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703670
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703672
Principal investigator 1 PFIZER INC. $120.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703674
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703676
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703678
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703680
Principal investigator 1 PFIZER INC. $335.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703732
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703734
Principal investigator 1 PFIZER INC. $96.48 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703738
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703742
Principal investigator 1 PFIZER INC. $1,658.70 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703744
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703746
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703750
Principal investigator 1 PFIZER INC. $100.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703752
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703754
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703760
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703762
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703814
Principal investigator 1 PFIZER INC. $1,000.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703816
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703818
Principal investigator 1 PFIZER INC. $207.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703822
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703824
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703830
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703832
Principal investigator 1 PFIZER INC. $75.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703838
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703840
Principal investigator 1 PFIZER INC. $100.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703854
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703856
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703858
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703896
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703902
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703904
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703906
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703908
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703910
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703912
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703914
Principal investigator 1 PFIZER INC. $207.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703916
Principal investigator 1 PFIZER INC. $200.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703918
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703920
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703922
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703980
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703982
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703984
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703992
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703994
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703996
Principal investigator 1 PFIZER INC. $103.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703998
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704000
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704002
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704004
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704006
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704008
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704034
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704036
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704038
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704040
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704042
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704044
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704046
Principal investigator 1 PFIZER INC. $75.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704062
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704064
Principal investigator 1 PFIZER INC. $172.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704068
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704070
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704072
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704076
Principal investigator 1 PFIZER INC. $300.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704078
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704080
Principal investigator 1 PFIZER INC. $75.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704082
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704084
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704088
Principal investigator 1 PFIZER INC. $103.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704090
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704122
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704124
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704126
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704128
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704130
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704140
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704142
Principal investigator 1 PFIZER INC. $103.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704144
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704146
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704148
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704150
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704152
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704156
Principal investigator 1 PFIZER INC. $100.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704158
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704160
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704162
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704196
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704198
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704200
Principal investigator 1 PFIZER INC. $120.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704202
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704204
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704206
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704210
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704212
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704214
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704232
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704234
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704236
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704238
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704240
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704242
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704244
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704246
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704248
Principal investigator 1 PFIZER INC. $100.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704252
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704254
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704272
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704274
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704276
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704280
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704282
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704284
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704286
Principal investigator 1 PFIZER INC. $1,200.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704288
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704290
Principal investigator 1 PFIZER INC. $100.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704292
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704294
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704314
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704316
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704320
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704322
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704324
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704326
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704330
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704332
Principal investigator 1 PFIZER INC. $172.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704360
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704362
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704364
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704366
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704372
Principal investigator 1 PFIZER INC. $96.48 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704374
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704376
Principal investigator 1 PFIZER INC. $75.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704382
Principal investigator 1 PFIZER INC. $75.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704484
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704486
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704490
Principal investigator 1 PFIZER INC. $75.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704492
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704494
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704496
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704498
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705432
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705434
Principal investigator 1 PFIZER INC. $1,200.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705436
Principal investigator 1 PFIZER INC. $96.48 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705438
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705440
Principal investigator 1 PFIZER INC. $96.48 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705448
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705466
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705468
Principal investigator 1 PFIZER INC. $1,000.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705474
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705476
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705480
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705552
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705554
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705556
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705560
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705564
Principal investigator 1 PFIZER INC. $207.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705566
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705568
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705570
Principal investigator 1 PFIZER INC. $1,810.57 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705602
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705604
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705606
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705608
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705610
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705612
Principal investigator 1 PFIZER INC. $75.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705614
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705618
Principal investigator 1 PFIZER INC. $100.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705648
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705650
Principal investigator 1 PFIZER INC. $100.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705652
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705660
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705662
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705664
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705692
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705694
Principal investigator 1 PFIZER INC. $120.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705696
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705698
Principal investigator 1 PFIZER INC. $207.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705700
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705752
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705760
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705762
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705764
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705766
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705808
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705810
Principal investigator 1 PFIZER INC. $172.50 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705812
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705886
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705893
Principal investigator 1 PFIZER INC. $375.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705982
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706110
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706114
Principal investigator 1 PFIZER INC. $1,810.57 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706118
Principal investigator 1 PFIZER INC. $75.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706363
Principal investigator 1 PFIZER INC. $103.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706367
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706488
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706495
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706499
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706600
Principal investigator 1 PFIZER INC. $120.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706603
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706629
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706633
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706636
Principal investigator 1 PFIZER INC. $100.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706791
Principal investigator 1 PFIZER INC. $207.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706793
Principal investigator 1 PFIZER INC. $500.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706799
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706801
Principal investigator 1 PFIZER INC. $25.00 04/18/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706803
Principal investigator 1 Travere Therapeutics, Inc. $25,016.91 04/18/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184264
Principal investigator 1 Travere Therapeutics, Inc. $136.44 04/18/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184268
Principal investigator 1 Travere Therapeutics, Inc. $9,448.55 04/17/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184257
Principal investigator 1 Travere Therapeutics, Inc. $64,509.42 04/17/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184260
Principal investigator 1 Travere Therapeutics, Inc. $1,610.18 04/07/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184248
Principal investigator 1 Travere Therapeutics, Inc. $129,148.00 04/07/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184252
Principal investigator 1 Travere Therapeutics, Inc. $29,961.28 04/01/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184506
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743040
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743044
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743052
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743058
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743060
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743062
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743064
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743066
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743070
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743072
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743074
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743080
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743086
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743088
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743106
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743108
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743110
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743120
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743126
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743130
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743140
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743142
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743168
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743170
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743172
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743184
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743188
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743204
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743206
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743208
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743216
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743222
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743234
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743240
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743250
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743252
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743266
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743272
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743274
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743280
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743294
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743296
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743298
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743306
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743312
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743314
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743316
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743320
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743332
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743338
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743344
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743354
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743356
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743368
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743372
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743374
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743380
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743382
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743392
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743402
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743404
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743406
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743408
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743410
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743412
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743428
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743432
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743440
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743446
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743450
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743468
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743470
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743474
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743480
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743488
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743490
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743508
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743514
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743526
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743532
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743554
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743556
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743558
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743562
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743566
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743570
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743574
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743576
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743592
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743598
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743600
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743602
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743608
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743614
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743618
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743620
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743622
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743628
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 03/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743632
Principal investigator 1 Travere Therapeutics, Inc. $14,908.17 03/25/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184498
Principal investigator 1 Travere Therapeutics, Inc. $92,683.90 03/25/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184502
Principal investigator 1 PFIZER INC. $655.20 03/20/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703230
Principal investigator 1 PFIZER INC. $1,354.95 03/20/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703990
Principal investigator 1 PFIZER INC. $1,354.95 03/20/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704208
Principal investigator 1 PFIZER INC. $655.20 03/20/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706513
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743042
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743046
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743048
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743068
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743078
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743084
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743090
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743094
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743102
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743104
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743112
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743114
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743116
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743124
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743128
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743134
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743146
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743152
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743156
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743158
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743174
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743178
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743180
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743186
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743190
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743192
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743198
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743200
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743202
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743214
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743224
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743232
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743236
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743244
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743248
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743260
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743264
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743276
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743278
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743282
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743288
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743292
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743300
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743302
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743318
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743322
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743324
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743330
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743334
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743340
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743342
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743346
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743348
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743352
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743366
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743376
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743384
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743386
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743390
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743396
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743398
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743400
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743414
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743420
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743424
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743426
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743430
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743434
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743436
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743442
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743444
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743454
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743460
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743464
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743476
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743484
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743486
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743492
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743494
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743496
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743498
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743500
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743502
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743506
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743510
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743518
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743520
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743538
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743548
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743552
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743564
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743578
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743580
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743586
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743588
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743596
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743606
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743624
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743636
Principal investigator 1 Travere Therapeutics, Inc. $12,783.86 02/24/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184528
Principal investigator 1 Travere Therapeutics, Inc. $89,893.54 02/24/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184533
Principal investigator 1 Travere Therapeutics, Inc. $4,274.10 02/24/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184537
Principal investigator 1 Travere Therapeutics, Inc. $81,065.20 02/24/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184541
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703162
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703222
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703240
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703246
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703258
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703260
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703320
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703326
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703332
Principal investigator 1 PFIZER INC. $1,082.25 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703438
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703736
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703748
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703828
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703836
Principal investigator 1 PFIZER INC. $1,082.25 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703900
Principal investigator 1 PFIZER INC. $1,124.10 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703986
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704032
Principal investigator 1 PFIZER INC. $1,082.25 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704074
Principal investigator 1 PFIZER INC. $1,082.25 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704216
Principal investigator 1 PFIZER INC. $1,124.10 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704230
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704312
Principal investigator 1 PFIZER INC. $1,082.25 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704328
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704358
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704368
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704370
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704378
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705442
Principal investigator 1 PFIZER INC. $1,628.33 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705444
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705446
Principal investigator 1 PFIZER INC. $1,304.55 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705482
Principal investigator 1 PFIZER INC. $1,082.25 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705562
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705702
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705758
Principal investigator 1 PFIZER INC. $1,544.40 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706239
Principal investigator 1 PFIZER INC. $655.20 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706243
Principal investigator 1 PFIZER INC. $1,628.33 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706504
Principal investigator 1 PFIZER INC. $2,865.29 02/19/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706508
Principal investigator 1 AstraZeneca UK Limited $108,424.05 02/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LOS ANGELES
a phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult participants with episodic migraine No dispute reported 06/30/2026 1185540599
Recipient Eli Lilly and Company $570.00 01/31/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187873845
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743050
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743054
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743056
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743076
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743082
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743092
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743096
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743098
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743100
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743118
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743122
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743132
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743136
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743148
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743150
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743154
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743160
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743162
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743164
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743166
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743176
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743182
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743194
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743196
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743210
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743212
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743218
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743220
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743226
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743228
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743230
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743238
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743242
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743246
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743254
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743256
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743258
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743262
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743268
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743270
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743284
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743286
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743290
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743304
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743308
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743310
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743326
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743328
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743336
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743350
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743358
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743360
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743362
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743364
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743370
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743378
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743388
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743394
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743416
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743418
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743422
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743438
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743448
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743452
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743456
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743458
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743462
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743466
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743472
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743478
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743482
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743504
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743512
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743516
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743522
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743524
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743528
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743530
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743534
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743536
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743540
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743542
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743544
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743546
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743550
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743560
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743568
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743572
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743582
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743584
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743590
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743594
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743604
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $36.40 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743610
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $143.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743612
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743616
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743626
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743630
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743634
Principal investigator 1 Travere Therapeutics, Inc. $5,112.15 01/27/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184518
Principal investigator 1 Travere Therapeutics, Inc. $97,408.62 01/27/2025 Non-covered Recipient Entity
Science 37 Inc
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency No dispute reported 06/30/2026 1244184522
Principal investigator 1 Travere Therapeutics, Inc. $12,427.84 01/21/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184510
Principal investigator 1 Travere Therapeutics, Inc. $58,784.16 01/21/2025 Non-covered Recipient Entity
Science 37 Inc
An Open-Label, Phase 3 Long-Term Extension (LTE) Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria (HCU) due to Cystathionine Beta Synthase Deficiency (ENSEMBLE) No dispute reported 06/30/2026 1244184514
Principal investigator 1 PFIZER INC. $2,047.50 01/18/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703554
Principal investigator 1 PFIZER INC. $2,865.29 01/18/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703898
Principal investigator 1 PFIZER INC. $2,047.50 01/18/2025 Non-covered Recipient Entity
Clinical Research Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705478
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $37.20 01/06/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743144
Principal investigator 1 Ipsen Innovation $600.00 01/03/2025 Non-covered Recipient Entity
Bnl Health, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289316
Principal investigator 1 Ipsen Innovation $180.00 01/03/2025 Non-covered Recipient Entity
Bnl Health, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289318
Principal investigator 1 ABBVIE INC. $1,070.10 01/02/2025 Non-covered Recipient Entity
LISA G COOK MD INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202433884
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $15.84 01/01/2025 Non-covered Recipient Entity
Science 37
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233743138
Principal investigator 1 PFIZER INC. $1,082.25 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703148
Principal investigator 1 PFIZER INC. $1,082.25 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703154
Principal investigator 1 PFIZER INC. $1,222.65 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703242
Principal investigator 1 PFIZER INC. $1,082.25 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703338
Principal investigator 1 PFIZER INC. $1,082.25 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703380
Principal investigator 1 PFIZER INC. $1,082.25 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703434
Principal investigator 1 PFIZER INC. $1,544.40 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703502
Principal investigator 1 PFIZER INC. $655.20 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703576
Principal investigator 1 PFIZER INC. $252.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703578
Principal investigator 1 PFIZER INC. $252.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703580
Principal investigator 1 PFIZER INC. $252.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703820
Principal investigator 1 PFIZER INC. $1,222.65 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703988
Principal investigator 1 PFIZER INC. $252.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704048
Principal investigator 1 PFIZER INC. $1,304.55 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704066
Principal investigator 1 PFIZER INC. $252.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704154
Principal investigator 1 PFIZER INC. $1,082.25 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704250
Principal investigator 1 PFIZER INC. $1,222.65 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704270
Principal investigator 1 PFIZER INC. $1,082.25 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704278
Principal investigator 1 PFIZER INC. $1,304.55 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704380
Principal investigator 1 PFIZER INC. $1,304.55 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704500
Principal investigator 1 PFIZER INC. $1,222.65 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705472
Principal investigator 1 PFIZER INC. $1,304.55 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705558
Principal investigator 1 PFIZER INC. $1,433.25 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705616
Principal investigator 1 PFIZER INC. $144.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705654
Principal investigator 1 PFIZER INC. $252.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705658
Principal investigator 1 PFIZER INC. $6,000.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705756
Principal investigator 1 PFIZER INC. $1,304.55 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706359
Principal investigator 1 PFIZER INC. $1,082.25 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706480
Principal investigator 1 PFIZER INC. $1,544.40 01/01/2025 Non-covered Recipient Entity
Clinical Research Institute LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706795